Firas El Chaer

Also affiliated with Baptist Health South Florida

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia”.

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Bone Marrow Transplantation(2024)10.1038/s41409-024-02449-2

N/A

0.480DataRank · unranked

10 citations

Niveditha Ravindra, Pranay S. Hegde, Georgia Andrew, Devdeep Mukherjee, Zoë C. Wong +18 more

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia

Bone Marrow Transplantation(2024)10.1038/s41409-024-02447-4

N/A

0.480DataRank · unranked

10 citations

Niveditha Ravindra, Pranay S. Hegde, Georgia Andrew, Devdeep Mukherjee, Zoë C. Wong +18 more

Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia

Bone Marrow Transplantation(2024)10.1038/s41409-024-02444-7

N/A

0.306DataRank · unranked

6 citations

Georgia Andrew, Gege Gui, Niveditha Ravindra, Devdeep Mukherjee, Zoë C. Wong +15 more

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

medRxiv(2023)10.1101/2023.07.28.23293166

N/A

0.184DataRank · unranked

2 citations

Laura W. Dillon, Niveditha Ravindra, Pranay S. Hegde, Georgia Andrew, Devdeep Mukherjee +17 more

Pre-MEASURE: FLT3 -ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission

medRxiv(2022)10.1101/2022.10.21.22281322

N/A

0.126DataRank · unranked

1 citations

Gege Gui, Niveditha Ravindra, Zoë C. Wong, Georgia Andrew, Devdeep Mukherjee +16 more

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Blood Advances(2021)10.1182/bloodadvances.2020003839

N/A

0DataRank · unranked

9 citations

Uma Borate, Rémy Duléry, Shernan G. Holtan, Arjun Law, Lori Muffly +8 more

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

Bone Marrow Transplantation(2025)10.1038/s41409-025-02757-1

N/A

0DataRank · unranked

2 citations

Gege Gui, Niveditha Ravindra, Georgia Andrew, Devdeep Mukherjee, Zoë C. Wong +23 more

Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.7006

N/A

0DataRank · unranked

11 citations

Laura W. Dillon, Gege Gui, Niveditha Ravindra, Zoë C. Wong, Georgia Andrew +15 more

How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines

Blood(2023)10.1182/blood.2022017808

N/A

0DataRank · unranked

47 citations

Christopher S. Hourigan, Amer M. Zeidan, Firas El Chaer

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

JAMA Oncology(2024)10.1001/jamaoncol.2024.0985

N/A

0DataRank · unranked

54 citations

Gege Gui, Niveditha Ravindra, Georgia Andrew, Devdeep Mukherjee, Zoë C. Wong +20 more

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Blood(2025)10.1182/blood.2024026655

N/A

0DataRank · unranked

26 citations

Alexander W. Rankin, Chloe Hoang, Alexandra Semchenkova, Regina M. Myers, Elena Zerkalenkova +76 more